ArticleAdvances in radiation oncology2026
Partially Ablative Body Radiation Therapy Versus Standard Palliative Radiation Therapy for Locally Advanced Bulky Unresectable Sarcomas.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Locally advanced soft tissue sarcomas cause significant tumor mass effects, often leading to onerous symptoms. Our institution has previously developed partially ablative body radiation therapy (PABR) for palliation in these circumstances, which has demonstrated effective symptom relief. However, these outcomes have not been compared with clinical outcomes from standard palliative radiation therapy (SPR). Methods and Materials: A total of 57 patients (30 PABR and 27 SPR) with various soft tissue sarcomas >5 cm in diameter treated between December 2019 and April 2024 were retrospectively reviewed. The primary endpoints were symptomatic and objective structural response rates and were compared using binomial regression. Secondary endpoints were overall survival, freedom from local progression, and freedom from distant progression. Results: The median age was 73 years and 56 years in the PABR and SPR groups, respectively. The median tumor volume was 898.55 cm Conclusions: PABR for bulky unresectable sarcomas may provide improved palliation of symptoms compared to SPR, with potentially better local control despite treating significantly larger tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.